These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18600079)

  • 1. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
    Batlle J; Villar A; Liras A; Alonso C; Altisent C; Brito D; Moreno M; Lucía F; Sedano C; Prieto M; Calvente N; Aznar JA; Jiménez V; Soriano V; Martorell JR; Iruín G; Bergua JM; Aguilar C
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):333-40. PubMed ID: 18600079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia.
    Angelotta C; McKoy JM; Fisher MJ; Buffie CG; Barfi K; Ramsey G; Frohlich L; Bennett CL
    Vox Sang; 2007 Aug; 93(2):159-65. PubMed ID: 17683360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious disease in the blood supply and the public health response.
    Evatt B
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S4-9. PubMed ID: 16631825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.
    Keeling D; Tait C; Makris M
    Haemophilia; 2008 Jul; 14(4):671-84. PubMed ID: 18422612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfusion-transmitted infection in hemophilia in developing countries.
    Yee TT; Lee CA
    Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and supply of haemophilia products: worldwide perspectives.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal haemophilia care versus the reality.
    Bolton-Maggs PH
    Br J Haematol; 2006 Mar; 132(6):671-82. PubMed ID: 16487168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral pathogens.
    Ragni MV; Sherman KE; Jordan JA
    Haemophilia; 2010 Jul; 16 Suppl 5():40-6. PubMed ID: 20590855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration in hemophilia therapy selection.
    Pipe S
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S23-7. PubMed ID: 16631824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Jan; 51(51-52):1152-4. PubMed ID: 12553567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilia: pathophysiology and management.
    Vidler V
    Nurs Times; 2003 Oct 14-20; 99(41):30-3. PubMed ID: 14603655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging and receding risks of therapeutic regimens for haemophilia.
    Farrugia A; Manno CS; Evatt BL
    Haemophilia; 2004 Oct; 10 Suppl 4():47-54. PubMed ID: 15479372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy.
    Mauser-Bunschoten EP; Fransen Van De Putte DE; Schutgens RE
    Haemophilia; 2009 Jul; 15(4):853-63. PubMed ID: 19228203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The physician's role in selecting a factor replacement therapy.
    Pipe SW
    Haemophilia; 2006 Mar; 12 Suppl 1():21-5; discussion 26-8. PubMed ID: 16445814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to treat and the benefits of treating hepatitis C in patients with haemophilia.
    Patel H; Heathcote EJ
    Haemophilia; 2009 Jan; 15(1):20-32. PubMed ID: 18976253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-morbidities and quality of life in elderly persons with haemophilia.
    Franchini M; Mannucci PM
    Br J Haematol; 2010 Feb; 148(4):522-33. PubMed ID: 19958358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of random versus apheresis platelet concentrates.
    Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
    Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Registry of inherited coagulopathies in Brazil: first report.
    Rezende SM; Pinheiro K; Caram C; Genovez G; Barca D
    Haemophilia; 2009 Jan; 15(1):142-9. PubMed ID: 18976255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.